Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report

Miki Koroku; Teppei Omori; Harutaka Kambayashi; Shun Murasugi; Tomoko Kuriyama; Yuichi Ikarashi; Maria Yonezawa; Ken Arimura; Kazunori Karasawa; Norio Hanafusa; Masatoshi Kawana; Katsutoshi Tokushige

doi:10.5217/ir.2020.00148

Intestinal Research (Jan 2022)

Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report

Miki Koroku,
Teppei Omori,
Harutaka Kambayashi,
Shun Murasugi,
Tomoko Kuriyama,
Yuichi Ikarashi,
Maria Yonezawa,
Ken Arimura,
Kazunori Karasawa,
Norio Hanafusa,
Masatoshi Kawana,
Katsutoshi Tokushige

Affiliations

Miki Koroku: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Teppei Omori: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Harutaka Kambayashi: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Shun Murasugi: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Tomoko Kuriyama: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Yuichi Ikarashi: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Maria Yonezawa: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Ken Arimura: Department of Respiratory Medicine, Tokyo Women’s Medical University, Tokyo, Japan
Kazunori Karasawa: Division of Nephrology, Department of Medicine, Tokyo Women’s Medical University, Tokyo, Japan
Norio Hanafusa: Department of Blood Purification, Tokyo Women’s Medical University, Tokyo, Japan
Masatoshi Kawana: Primary Care Center, Tokyo Women’s Medical University, Tokyo, Japan
Katsutoshi Tokushige: Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan

DOI: https://doi.org/10.5217/ir.2020.00148
Journal volume & issue: Vol. 20, no. 1
pp. 150 – 155

Abstract

Read online

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.

Published in Intestinal Research

ISSN: 1598-9100 (Print); 2288-1956 (Online)
Publisher: Korean Association for the Study of Intestinal Diseases
Country of publisher: Korea, Republic of
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: http://www.irjournal.org

About the journal

Abstract

Keywords